BC Week In Review | Nov 30, 2018
Clinical News

Stallergenes Phase III data for sublingual allergy tablet support U.S. and EU submissions

Stallergenes Greer plc (Euronext:STAGR) said its once-daily house dust mite sublingual tablet (STAGR320) met the primary endpoint in a Phase III trial to treat house dust mite-induced allergic rhinitis. The company said the data support...
BC Week In Review | Sep 29, 2017
Clinical News

Stallergenes completes enrollment in Phase III trial of dust mite allergy tablet Actair

Stallergenes Greer plc (Euronext:STAGR) completed enrollment of over 1,600 patients in a Phase III trial of once-daily Actair house dust mites sublingual tablet (S-524101, STG320) to treat house dust mite-induced allergic rhinitis. The double-blind, placebo-controlled,...
BC Week In Review | Mar 31, 2017
Clinical News

Actair regulatory update

Shionogi submitted a regulatory application in Japan for Actair house dust mite sublingual tablet to treat allergic rhinitis caused by house dust mites in patients ages 5-11. The sublingual immunotherapy tablets are already approved for...
BC Week In Review | Feb 3, 2017
Clinical News

STG320: Ph III data

Top-line data from a double-blind, Japanese Phase III trial in 438 patients ages 5-16 with perennial, house dust mite-induced allergic rhinitis showed that once-daily sublingual STG320 for 12 months met the primary endpoint of improving...
BioCentury | Mar 17, 2014
Finance

Circassia raises expectations

The largest-ever European biotech IPO - by Circassia Pharmaceuticals plc - plus three new filings have buysiders thinking the crack in a European IPO window could be widening. But if Circassia doesn't perform, it could once again...
BC Week In Review | Feb 24, 2014
Clinical News

House dust mites sublingual immunotherapy tablet: Phase II/III data

Stallergenes said partner Shionogi reported data from the double-blind, Japanese Phase II/III S-524101 trial showing that house dust mites sublingual immunotherapy tablet met the primary endpoint of improving Average Adjusted Symptom Score over 1 year...
BC Week In Review | May 14, 2012
Clinical News

House dust mites sublingual immunotherapy tablet: Phase II data

The dose-ranging, double-blind, Canadian Phase II VO67.10 trial in 355 adults with house dust mite allergic rhinitis showed that the once-daily 500 IR dose of Stallergenes' house dust mites sublingual immunotherapy tablet met the primary...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Flavored with Phase III

The upcoming clinical and regulatory calendar isn't as densely packed as it was in the first half. But biotech investors are looking especially to Phase III data across all market cap segments through year end....
BioCentury | Apr 4, 2011
Finance

ASCO and Beyond

The second quarter docket is full of clinical and regulatory milestones, as well as early reports of sales for a number of newly launched products. Foremost among the events this quarter is the American Society...
BC Week In Review | Sep 13, 2010
Company News

Stallergenes, Shionogi deal

Stallergenes granted Shionogi exclusive rights to develop and commercialize allergy candidate Actair in Japan and Taiwan. The sublingual desensitization tablet to treat house dust mites allergies is in Phase III testing. Shionogi also received rights...
Items per page:
1 - 10 of 12